[Effect of PSK on cell-mediated immune status in the patients of stomach cancer].
Among 56 patients with stomach cancer preoperative cell-mediated immunity in relation to clinical staging was studied: eight cases were subjected to a control study in order to evaluate effects of PSK on cell-mediated immune status, preoperatively and postoperatively at 1, 3, 6, 9 and 12 months. They were given MMC and FT-207, and 4 of them (the study group) received PSK in addition. Preoperative study showed that WBC count, peripheral lymphocyte and T-lymphocyte tended to show a decrease as the disease progressed, whereas there was no major change in PHA response of lymphocytes. Postoperative study on 4 control patients showed that peripheral lymphocyte and T lymphocyte decreased, and that IgG X FcR+ T cells significantly increased during postoperative period. Four patients in the study group who received PSK, however, did not show these characteristics. It thus appears that PSK is effective in activating cell, while immunity during postoperative period, possibly by counterworking suppressor cells including IgG X FcR+T cells.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011184:Postoperative Period; D011509:Proteoglycans / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000276:immunology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D011509:Proteoglycans; D005641:Tegafur; C010770:polysaccharide-K; D016685:Mitomycin